SPRAVATO An Alternative For Treatment-Resistant Depression - Midtown Psychiatry and TMS Center Houston, TX
SPRAVATO™ is the only NMDA receptor antagonist approved in conjunction with an oral antidepressant for treatment-resistant depression. It contains esketamine, an alternative to ketamine, and is a schedule III-controlled substance, and it has been studied to help in the treatment of depression.